Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 negative
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 6 days (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 6d
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 6 days
pembrolizumab
Sensitive
:
A2
NCCN - 6 days - (New A2)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
TC
Sensitive: A2 - Guideline
TC
Sensitive
:
A2
TC
Sensitive: A2 - Guideline
TC
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
fulvestrant
Sensitive: A2 - Guideline
fulvestrant
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + anastrozole
Sensitive: A2 - Guideline
fulvestrant + anastrozole
Sensitive
:
A2
fulvestrant + anastrozole
Sensitive: A2 - Guideline
fulvestrant + anastrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + letrozole
Sensitive: A2 - Guideline
fulvestrant + letrozole
Sensitive
:
A2
fulvestrant + letrozole
Sensitive: A2 - Guideline
fulvestrant + letrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
exemestane
Sensitive
:
A2
exemestane
Sensitive: A2 - Guideline
exemestane
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login